Discussion
Leukemia is a heterogeneous group of malignant clonal diseases of the hematopoietic tissue belonging to the group of hemoblastoses. Pathological disorders in the bone marrow lead to secondary immunodeficiency, as a result of which the disease becomes systemic.
According to Chinese researchers, patients with cancer have worse outcomes from COVID-19, which suggests that this group should be given more attention (12). Three main strategies are proposed for patients with cancer during the COVID-19 pandemic and in the event of severe infectious complications. First, in endemic regions, consideration should be given to deferring chemotherapy and routine hospitalization. Secondly, more stringent personal protection measures for cancer patients should be envisaged. Third, more intensive monitoring or treatment should be considered when patients are infected with SARS-CoV-2 (12). The department for the treatment of patients with hematological malignancies with concomitant COVID-19 has been operating since June 2020. During this period, 19 patients were treated, of which: men - 11, women - 8. The average age was 43 years (+-16). Of these, patients with multiple myeloma-32%; acute myeloid leukemia - 26%; acute promyelocytic leukemia - 11%; acute lymphoblastic leukemia - 26%; chronic lymphocytic leukemia - 5%. In our center, we have chosen the tactics of conducting complex therapy for patients with hemoblastosis and hematopoietic depression with COVID-19 without interrupting chemotherapy. According to our preliminary observation, chemotherapy does not worsen the course of COVID-19 and does not increase early mortality after chemotherapy.